Paradoxically, anti-inflammatory therapies, especially TNFa inhibitors and methotrexate, coincide with an increase in an overall increase of lipid components, but mostly HDL, which improves the TC/HDL ratio in patients with RA, and this lipid profile is associated with a reduction in the number of CV events, which is probably due to the anti-inflammatory effect and subsequent suppression of RA-associated inflammation [93,94,95]. Here, TNF is linked to rheumatoid arthritis.